Saccharomyces Boulardii Protease Inhibits the Effects of Clostridium Difficile Toxins A and B in Human Colonic Mucosa

Overview

Journal Infect Immun

Publisher American Society for Microbiology

Specialty Allergy & Immunology

Date 1998 Dec 24

PMID 9864230

Citations 111

Authors

I Castagliuolo

M F Riegler

L Valenick

J T Lamont

C Pothoulakis

Affiliations

Soon will be listed here.

Abstract

Saccharomyces boulardii is a nonpathogenic yeast used in the treatment of Clostridium difficile diarrhea and colitis. We have reported that S. boulardii inhibits C. difficile toxin A enteritis in rats by releasing a 54-kDa protease which digests the toxin A molecule and its brush border membrane (BBM) receptor (I. Castagliuolo, J. T. LaMont, S. T. Nikulasson, and C. Pothoulakis, Infect. Immun. 64:5225-5232, 1996). The aim of this study was to further evaluate the role of S. boulardii protease in preventing C. difficile toxin A enteritis in rat ileum and determine whether it protects human colonic mucosa from C. difficile toxins. A polyclonal rabbit antiserum raised against purified S. boulardii serine protease inhibited by 73% the proteolytic activity present in S. boulardii conditioned medium in vitro. The anti-protease immunoglobulin G (IgG) prevented the action of S. boulardii on toxin A-induced intestinal secretion and mucosal permeability to [3H]mannitol in rat ileal loops, while control rabbit IgG had no effect. The anti-protease IgG also prevented the effects of S. boulardii protease on digestion of toxins A and B and on binding of [3H]toxin A and [3H]toxin B to purified human colonic BBM. Purified S. boulardii protease reversed toxin A- and toxin B-induced inhibition of protein synthesis in human colonic (HT-29) cells. Furthermore, toxin A- and B-induced drops in transepithelial resistance in human colonic mucosa mounted in Ussing chambers were reversed by 60 and 68%, respectively, by preexposing the toxins to S. boulardii protease. We conclude that the protective effects of S. boulardii on C. difficile-induced inflammatory diarrhea in humans are due, at least in part, to proteolytic digestion of toxin A and B molecules by a secreted protease.

Citing Articles

Action and immunomodulatory mechanisms, formulations, and safety concerns of probiotics.

Ashaolu T, Greff B, Varga L Biosci Microbiota Food Health. 2025; 44(1):4-15.

PMID: 39764491 PMC: 11700557. DOI: 10.12938/bmfh.2024-006.

Effects of probiotics in elderly hospitalized tube-fed patients with antibiotics use.

Hsia C, Su H, Chen Y, Chuang H, Chien Y BMC Gastroenterol. 2024; 24(1):467.

PMID: 39702125 PMC: 11660702. DOI: 10.1186/s12876-024-03561-9.

The mycobiome as integral part of the gut microbiome: crucial role of symbiotic fungi in health and disease.

Huang H, Wang Q, Yang Y, Zhong W, He F, Li J Gut Microbes. 2024; 16(1):2440111.

PMID: 39676474 PMC: 11651280. DOI: 10.1080/19490976.2024.2440111.

Next-Generation Probiotics and Chronic Diseases: A Review of Current Research and Future Directions.

Tiwari A, Krisnawati D, Susilowati E, Mutalik C, Kuo T J Agric Food Chem. 2024; 72(50):27679-27700.

PMID: 39588716 PMC: 11660543. DOI: 10.1021/acs.jafc.4c08702.

Investigation of the impact of multi-strain probiotics containing on porcine production.

Kim S, Cho J, Keum G, Kwak J, Doo H, Choi Y J Anim Sci Technol. 2024; 66(5):876-890.

PMID: 39398307 PMC: 11466735. DOI: 10.5187/jast.2024.e79.

References

Laemmli U . Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970; 227(5259):680-5. DOI: 10.1038/227680a0. View

Roth J, Losty T, Wierbicki E . Assay of proteolytic enzyme activity using a 14C-labeled hemoglobin. Anal Biochem. 1971; 42(1):214-21. DOI: 10.1016/0003-2697(71)90029-7. View

Bartlett J, Onderdonk A, Cisneros R, Kasper D . Clindamycin-associated colitis due to a toxin-producing species of Clostridium in hamsters. J Infect Dis. 1977; 136(5):701-5. DOI: 10.1093/infdis/136.5.701. View

Bartlett J, Chang T, Gurwith M, Gorbach S, Onderdonk A . Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia. N Engl J Med. 1978; 298(10):531-4. DOI: 10.1056/NEJM197803092981003. View

McClane B, McDonel J . The effects of Clostridium perfringens enterotoxin on morphology, viability, and macromolecular synthesis in Vero cells. J Cell Physiol. 1979; 99(2):191-200. DOI: 10.1002/jcp.1040990205. View

SULLIVAN N, Pellett S, Wilkins T . Purification and characterization of toxins A and B of Clostridium difficile. Infect Immun. 1982; 35(3):1032-40. PMC: 351151. DOI: 10.1128/iai.35.3.1032-1040.1982. View

MASSOT J, Sanchez O, Couchy R, Astoin J, Parodi A . Bacterio-pharmacological activity of Saccharomyces boulardii in clindamycin-induced colitis in the hamster. Arzneimittelforschung. 1984; 34(7):794-7. View

Toothaker R, Elmer G . Prevention of clindamycin-induced mortality in hamsters by Saccharomyces boulardii. Antimicrob Agents Chemother. 1984; 26(4):552-6. PMC: 179962. DOI: 10.1128/AAC.26.4.552. View

Pothoulakis C, Barone L, Ely R, Faris B, Clark M, Franzblau C . Purification and properties of Clostridium difficile cytotoxin B. J Biol Chem. 1986; 261(3):1316-21. View

10.

Buts J, Bernasconi P, Van Craynest M, Maldague P, DE MEYER R . Response of human and rat small intestinal mucosa to oral administration of Saccharomyces boulardii. Pediatr Res. 1986; 20(2):192-6. DOI: 10.1203/00006450-198602000-00020. View

11.

Pothoulakis C, Triadafilopoulos G, Clark M, Franzblau C, Lamont J . Clostridium difficile cytotoxin inhibits protein synthesis in fibroblasts and intestinal mucosa. Gastroenterology. 1986; 91(5):1147-53. DOI: 10.1016/s0016-5085(86)80010-5. View

12.

Corthier G, Dubos F, Ducluzeau R . Prevention of Clostridium difficile induced mortality in gnotobiotic mice by Saccharomyces boulardii. Can J Microbiol. 1986; 32(11):894-6. DOI: 10.1139/m86-164. View

13.

Elmer G, McFarland L . Suppression by Saccharomyces boulardii of toxigenic Clostridium difficile overgrowth after vancomycin treatment in hamsters. Antimicrob Agents Chemother. 1987; 31(1):129-31. PMC: 174670. DOI: 10.1128/AAC.31.1.129. View

14.

Triadafilopoulos G, Pothoulakis C, OBrien M, Lamont J . Differential effects of Clostridium difficile toxins A and B on rabbit ileum. Gastroenterology. 1987; 93(2):273-9. DOI: 10.1016/0016-5085(87)91014-6. View

15.

Hecht G, Pothoulakis C, Lamont J, Madara J . Clostridium difficile toxin A perturbs cytoskeletal structure and tight junction permeability of cultured human intestinal epithelial monolayers. J Clin Invest. 1988; 82(5):1516-24. PMC: 442717. DOI: 10.1172/JCI113760. View

16.

Lyerly D, Krivan H, Wilkins T . Clostridium difficile: its disease and toxins. Clin Microbiol Rev. 1988; 1(1):1-18. PMC: 358025. DOI: 10.1128/CMR.1.1.1. View

17.

McFarland L, Mulligan M, Kwok R, Stamm W . Nosocomial acquisition of Clostridium difficile infection. N Engl J Med. 1989; 320(4):204-10. DOI: 10.1056/NEJM198901263200402. View

18.

Surawicz C, Elmer G, Speelman P, McFarland L, CHINN J, van Belle G . Prevention of antibiotic-associated diarrhea by Saccharomyces boulardii: a prospective study. Gastroenterology. 1989; 96(4):981-8. DOI: 10.1016/0016-5085(89)91613-2. View

19.

Castex F, Corthier G, Jouvert S, Elmer G, Lucas F, Bastide M . Prevention of Clostridium difficile-induced experimental pseudomembranous colitis by Saccharomyces boulardii: a scanning electron microscopic and microbiological study. J Gen Microbiol. 1990; 136(6):1085-9. DOI: 10.1099/00221287-136-6-1085. View

20.

Pothoulakis C, Lamont J, Eglow R, Gao N, Rubins J, Theoharides T . Characterization of rabbit ileal receptors for Clostridium difficile toxin A. Evidence for a receptor-coupled G protein. J Clin Invest. 1991; 88(1):119-25. PMC: 296011. DOI: 10.1172/JCI115267. View